# Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta

- Link: https://www.thailand-business-news.com/pr-news/biosidus-expands-biologics-manufacturing-capacity-and-strengthens-global-supply-capabilities-for-agalsidase-beta
- Published: 2026-08-27T04:00:00+07:00
- Author: PR Newswire

BUENOS AIRES, Argentina, Aug. 27, 2026 /PRNewswire/ — Biosidus, an Argentine biotechnology
company with more than four decades of experience in the development and manufacturing
of biosimilar medicines, announced that its new bioreactor plant is now operational,
increasing the company’s biologics production capacity and reinforcing its ability
to support potential international demand.

 [⌊Biosidus works to improve people's quality of life.⌉](https://mmx.prnasia.com/media/MS1976323/shutterstock_2117314604.jpg?id=OA2914544&p=medium600)

Biosidus works to improve people’s quality of life.

The expansion strengthens Biosidus’ industrial platform at a time when healthcare
systems are placing increasing emphasis on manufacturing reliability, continuity
of treatment and diversified sources of complex biologic medicines.

Developed and manufactured in Argentina, Biosidus’ agalsidase beta, its biosimilar
enzyme replacement therapy for Fabry disease, represents a significant milestone
in the company’s biotechnology platform and its growing focus on treatments for 
rare diseases.

With additional production capacity, Biosidus is strengthening its international
supply capabilities and is prepared to engage with partners and health authorities
evaluating sustainable and reliable sources of agalsidase beta supply.

"Continuity of treatment is particularly critical for patients living with rare 
and chronic diseases. Expanding our productive capacity reinforces our commitment
to making Biosidus’ biotechnology capabilities available to healthcare systems seeking
sustainable and reliable access to high-quality biologic medicines," said Mario 
Koch, Director of Rare Diseases.

After launching agalsidase beta in Argentina in 2025, Biosidus is advancing the 
international expansion of its program and is available to evaluate extraordinary
supply requirements in markets where the applicable regulatory pathways allow it.

The new bioreactor capacity is part of Biosidus’ broader strategy of combining scientific
capabilities, local manufacturing, industrial investment and international expansion
to increase access to complex biologic therapies.

**About Biosidus**

Biosidus is an Argentine biotechnology company specializing in the development, 
manufacturing and commercialization of biosimilar medicines. With more than 40 years
of experience in biotechnology and a presence in international markets, the company
develops and manufactures complex biologic medicines across multiple therapeutic
areas.

---

  |  This article was produced by Cision PR Newswire, our trusted news partner. The views expressed and the content presented here are solely those of the author and may not fully reflect the opinions of Thailand Business News. |

---

 
**Read the original article :** [Biosidus expands biologics manufacturing capacity and strengthens global supply capabilities for agalsidase beta ](http://www.prnasia.com/story/archive/5034399_AE34399_0?rand=184833)